Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial

James N Ingle, Dongsheng Tu, Joseph L Pater, Silvana Martino, Nicholas J Robert, Hyman B Muss, Martine J Piccart, Monica Castiglione, Lois E Shepherd, Kathleen I Pritchard, Robert B Livingston, Nancy E Davidson, Larry Norton, Edith A Perez, Jeffrey S Abrams, David A Cameron, Michael J Palmer, Paul E Goss

Research output: Contribution to journalArticlepeer-review

Abstract

MA.17 was a double-blind placebo-controlled trial involving 5187 postmenopausal women that established letrozole to be of value in reducing recurrence of breast cancer when given in the extended adjuvant therapy setting after about 5 years of tamoxifen. Analyses were conducted to examine the relationships between duration of treatment on MA.17 and outcomes.
Original languageEnglish
Pages (from-to)295-300
Number of pages6
JournalBreast cancer research and treatment
Volume99
Issue number3
DOIs
Publication statusPublished - Oct 2006

Keywords

  • Aged
  • Antineoplastic Agents
  • Aromatase Inhibitors
  • Breast Neoplasms
  • Chemotherapy, Adjuvant
  • Disease-Free Survival
  • Double-Blind Method
  • Drug Administration Schedule
  • Female
  • Humans
  • Middle Aged
  • Nitriles
  • Postmenopause
  • Proportional Hazards Models
  • Receptors, Estrogen
  • Receptors, Progesterone
  • Selective Estrogen Receptor Modulators
  • Survival Analysis
  • Tamoxifen
  • Time Factors
  • Treatment Outcome
  • Triazoles

Fingerprint

Dive into the research topics of 'Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial'. Together they form a unique fingerprint.

Cite this